ABCB1 and lung adenocarcinoma: ABCB1 inhibitors can overcome resistance to CDDP [20], doxorubicin (DXR, an anthracycline antibiotic) [21], and paclitaxel (a taxane-derived chemotherapeutic agent) [22], in human lung adenocarcinoma cells.